Bryxta 100mg Injection

Bryxta 100mg Injection is an anti-cancer medication prescribed by the healthcare professional. The medication is used in the treatment of colorectal cancer. It consists of an active ingredient of Bevacizumab, which is a monoclonal antibody that works by inhibiting the vascular endothelial growth factor (VEGF), and preventing the growth of new blood vessels that tumor needs to grow and spread. Medication should be taken only under doctor prescription to ensure safe and effective treatment.

Colorectal cancer

Like any other medication Bryxta 100mg Injection also causes certain side effects, some patients may resolve on their own and some need proper medical attention. Consult the doctor If the symptoms persist:
● Headache
● Vision changes
● Confusion
● Severe allergic reactions
● High Blood pressure
● Numbness in hands or feet
● Weakness and lack of energy
● Diarrhea, nausea, vomiting, abdominal pain
● Constipation
● Loss of appetite

Bryxta 100mg Injection should be taken with or without food at the fixed time everyday to enhance the effectiveness of the medication. The correct dosage and duration must be administered only by the healthcare professional. Do not chew or crush the medication just take it with a whole glass of water.

Bryxta 100mg Injection works as a targeted therapy. It binds to the protein called vascular endothelial growth factor (VEGF). This inhibits the formation of blood vessels that supply oxygen and nutrient to the tumor. As a result, it slows down the rate of progression of cancer and stops the multiplication of cancer cells in the body.

• Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. (2010). Bevacizumab. The oncologist, 15(8), 819.
• Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012). Bevacizumab: overview of the literature. Expert review of anticancer therapy, 12(5), 567-580.
• Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer treatment reviews, 86, 102017.
• Ellis, L. M., & Kirkpatrick, P. (2005). Bevacizumab. Nature reviews Drug discovery, 4.
• Mukherji, S. K. (2010). Bevacizumab (avastin). American journal of neuroradiology, 31(2), 235-236